,Gene_set,Term,Overlap,P-value,Adjusted P-value,Odds Ratio,Genes,group,ordered_group,sample
2,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.008403361344537815,0.037815126050420166,158.33333333333334,ADAM10_NOTCH2,2,2,A1
7,gs_ind_0,Signaling by NOTCH2,1/1,0.008403361344537815,0.037815126050420166,158.33333333333334,ADAM10_NOTCH2,2,2,A1
9,gs_ind_0,ECM-receptor interaction,30/101,0.0008572218129518902,0.044575534273498287,2.361013370865588,LAMA5_ITGB4;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;TNC_SDC4;FN1_ITGB6;LAMA5_ITGB1;LAMA2_ITGB4;LAMC2_ITGA2;COL6A1_ITGB1;TNC_SDC1;FN1_ITGB1;THBS1_ITGA3;FN1_ITGA3;COMP_ITGB1;LAMB2_ITGA3;TNC_ITGB6;LAMC2_ITGB1;TNC_ITGAV;LAMB3_ITGB1;LAMB2_ITGB4;COL1A2_ITGB1;COL1A1_ITGB1;LAMC2_ITGA3;LAMB1_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;THBS1_ITGB1;LAMC2_ITGB4,3,3,A1
0,gs_ind_0,Antigen processing and presentation,2/2,0.00436442989634479,0.04800872885979268,16.103448275862068,HLA-B_KLRD1;HLA-E_KLRD1,1,1,B1
7,gs_ind_0,Graft-versus-host disease,2/2,0.00436442989634479,0.04800872885979268,16.103448275862068,HLA-B_KLRD1;HLA-E_KLRD1,1,1,B1
0,gs_ind_0,Antigen processing and presentation,2/2,0.002000363702491362,0.016002909619930897,24.57894736842105,HLA-B_KLRD1;HLA-E_KLRD1,4,4,B1
8,gs_ind_0,Graft-versus-host disease,2/2,0.002000363702491362,0.016002909619930897,24.57894736842105,HLA-B_KLRD1;HLA-E_KLRD1,4,4,B1
0,gs_ind_0,Antigen processing and presentation,2/2,0.0009322665943453793,0.015848532103871448,36.05263157894737,HLA-B_KLRD1;HLA-E_KLRD1,1,1,C1
6,gs_ind_0,Graft-versus-host disease,2/3,0.002747733120175855,0.02335573152149477,25.67669172932331,HLA-B_KLRD1;HLA-E_KLRD1,1,1,C1
21,gs_ind_0,Signaling by ERBB2,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
22,gs_ind_0,Signaling by ERBB2 ECD mutants,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
23,gs_ind_0,Signaling by ERBB2 KD Mutants,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
24,gs_ind_0,Signaling by ERBB2 in Cancer,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
0,gs_ind_0,Legionellosis,1/1,0.006756756756756758,0.010135135135135137,295.0,C3_ITGB2,1,1,F1
1,gs_ind_0,Leishmaniasis,1/1,0.006756756756756758,0.010135135135135137,295.0,C3_ITGB2,1,1,F1
2,gs_ind_0,Tuberculosis,1/3,0.020270270270270275,0.020270270270270275,124.71428571428571,C3_ITGB2,1,1,F1
4,gs_ind_0,ECM-receptor interaction,42/119,1.5530828049359555e-08,3.8827070123398885e-07,4.132881258115712,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;TNC_SDC4;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;TNC_SDC1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;THBS2_CD36;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1;THBS1_CD36,1,1,G2
6,gs_ind_0,Focal adhesion,42/127,2.188816225589337e-07,2.736020281986671e-06,3.689655172413793,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;VEGFA_EGFR;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
7,gs_ind_0,Human papillomavirus infection,41/133,5.8001572819980804e-06,4.833464401665067e-05,3.0985864443639,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
12,gs_ind_0,PI3K-Akt signaling pathway,42/147,5.096846346772992e-05,0.000318552896673312,2.7919345412039744,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;VEGFA_EGFR;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
15,gs_ind_0,Platelet activation,6/8,0.0008867961826742054,0.004433980913371027,4.232382061735585,COL3A1_ITGB1;COL1A1_ITGA2;COL1A2_ITGA2;COL1A2_ITGB1;COL1A1_ITGB1;COL3A1_ITGA2,1,1,G2
16,gs_ind_0,Proteoglycans in cancer,10/20,0.0014172569658998796,0.005905237357916165,2.9464988198269078,FN1_ITGAV;HSPG2_ITGA2;FN1_SDC2;COL1A2_ITGA2;HSPG2_ITGB1;COL1A1_ITGA2;FN1_ITGB1;FN1_ITGA2;COL1A2_ITGB1;COL1A1_ITGB1,1,1,G2
20,gs_ind_0,Small cell lung cancer,19/55,0.002468708657933648,0.008816816635477313,2.1783783783783783,COL4A5_ITGB1;LAMC1_ITGB1;LAMB2_ITGB1;FN1_ITGA6;LAMB3_ITGA2;COL4A5_ITGA2;LAMA5_ITGB1;COL4A6_ITGAV;COL4A6_ITGB1;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COL4A5_ITGAV;COL4A1_ITGB1;LAMC1_ITGA2;LAMB3_ITGB1;FN1_ITGA2;FN1_ITGAV;COL4A6_ITGA2,1,1,G2
0,gs_ind_0,Antigen processing and presentation,2/2,0.003246519010172426,0.03571170911189669,19.470588235294116,HLA-B_KLRD1;HLA-E_KLRD1,2,2,H1
7,gs_ind_0,Graft-versus-host disease,2/2,0.003246519010172426,0.03571170911189669,19.470588235294116,HLA-B_KLRD1;HLA-E_KLRD1,2,2,H1
1,gs_ind_0,ECM-receptor interaction,8/61,0.005184983933425765,0.016851197783633736,5.88780487804878,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
3,gs_ind_0,Focal adhesion,8/60,0.004576578320096527,0.016851197783633736,6.041322314049586,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
4,gs_ind_0,Human papillomavirus infection,8/67,0.010419991795540021,0.025164116818885352,5.062222222222222,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
5,gs_ind_0,PI3K-Akt signaling pathway,8/68,0.011614207762562471,0.025164116818885352,4.938686131386861,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
7,gs_ind_0,Platelet activation,3/3,0.00015740698231139031,0.002046290770048074,21.933333333333334,COL1A2_ITGB1;COL3A1_ITGB1;COL1A1_ITGB1,5,5,H1
8,gs_ind_0,Proteoglycans in cancer,4/10,0.0011771952764184797,0.007651769296720117,10.384615384615385,COL1A2_ITGB1;HSPG2_ITGB1;COL1A1_ITGB1;FN1_ITGB1,5,5,H1
6,gs_ind_0,Chemokine signaling pathway,8/16,0.0006711992438953861,0.02617677051192006,4.218673218673219,CXCL14_CXCR4;CXCL9_CXCR3;CCL21_CXCR3;CXCL12_CXCR4;CCL19_CXCR3;CCL21_CCR7;CCL19_CCR7;CCL5_CXCR3,6,6,H1
